Setipiprant

Cat. No.: HY-16635
CAS No.: 866460-33-5
Molecular Formula: C₂₄H₁₉FN₂O₃
Molecular Weight: 402.42
Target: Prostaglandin Receptor
Pathway: GPCR/G Protein
Storage: Powder
-20°C 3 years
4°C 2 years
In solvent
-80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro

DMSO : ≥ 36 mg/mL (89.46 mM)

"≥" means soluble, but saturation unknown.

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.4850 mL</td>
<td>12.4248 mL</td>
<td>24.8497 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4970 mL</td>
<td>2.4850 mL</td>
<td>4.9699 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2485 mL</td>
<td>1.2425 mL</td>
<td>2.4850 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
Setipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2. IC₅₀ value: 6.0 nMTarget: PGD2
in vitro: Setipiprant is an orally available, selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T helper [Th]-2 cells) antagonist. CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2). PGD2 is produced by the mast cells and is a key mediator in various inflammatory diseases, including allergy and asthma. Binding of PGD2 to CRTH2, which are expressed on the surface of blood-borne cells, induces chemotaxis of Th2 cells, basophils, and eosinophils, and stimulates cytokine release from these cells. Thus, antagonism of CRTH2 receptors is considered to be a promising therapeutic target for various allergic diseases and asthma.

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898    Fax: 609-228-5909    E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA